Cited by 622Advanced Polymer Synthesis and CharacterizationAdvanced Drug Delivery SystemsNanoparticle-Based Drug Delivery

Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation

Pelegri-O’Day, Emma M., Lin, En-Wei, Maynard, Heather D.·2014·Journal of the American Chemical Society

Abstract

Protein-polymer conjugates are widely used as therapeutics. All Food and Drug Administration (FDA)-approved protein conjugates are covalently linked to poly(ethylene glycol) (PEG). These PEGylated drugs have longer half-lives in the bloodstream, leading to less frequent dosing, which is a significant advantage for patients. However, there are some potential drawbacks to PEG that are driving the development of alternatives. Polymers that display enhanced pharmacokinetic properties along with additional advantages such as improved stability or degradability will be important to advance the field of protein therapeutics. This perspective presents a summary of protein-PEG conjugates for therapeutic use and alternative technologies in various stages of development as well as suggestions for future directions. Established methods of producing protein-PEG conjugates and new approaches utilizing controlled radical polymerization are also covered.

Integrity signals

Registry

Crossref · 10.1021/ja504390x

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Protein-polymer conjugates with polyethylene glycol (PEG) have improved their half-life, increased physical stability, and rendered them immune-free.

    “Protein-polymer conjugates polyethylene glycol (PEG) have improved their half-life, increased the physical stability, and rendered them immune-free.24”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [24]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pelegri-O’Day, E. M., Lin, E.-W., & Maynard, H. D.
Affiliations
California NanoSystems Institute (US)
Corresponding author
Maynard, Heather D.
Venue
Journal of the American Chemical Society
Published
2014-09-30
Volume
136
Issue
41
Pages
14323-14332
ISSN
  • 0002-7863 (ISSN-L)
  • 1520-5126
OpenAlex
W2315302880
Cited by
622
References
116
Citations by year
2026: 23 · 2025: 30 · 2024: 42 · 2023: 50 · 2022: 51 · 2021: 50 · 2020: 69 · 2019: 59 · 2018: 75 · 2017: 58 · 2016: 64 · 2015: 46 · 2014: 4
FWCI
25.25
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the American Chemical Society (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Division of Chemistry (CHE-1112550)
  • Department of Chemistry and Biochemistry, University of California, Los Angeles
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Advanced Polymer Synthesis and Characterization
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
protein-polymer conjugates, PEGylation, polyethylene glycol, therapeutic proteins, pharmacokinetics, half-life extension, controlled radical polymerization, drug stability, conjugation methods
MeSH terms
Models, Molecular, Polyethylene Glycols, Proteins, Molecular Structure, Polymerization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review